Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study.

Journal:

Journal of Clinical Oncology

Published:

2025-09-04

DOI:

10.1200/jco-25-00272

Affiliations:

22

Authors:

20

Go to article

Institutions	Authors	Share
Merck Group, Germany	2.000000	0.10
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.500000	0.08
Maria Sklodowska-Curie National Research Institute of Oncology, Poland	1.000000	0.05
National Cancer Center Hospital East, Japan	1.000000	0.05
Debiopharm Group, Switzerland	1.000000	0.05
Mardaleishvili Medical Centre, Georgia	1.000000	0.05
University Hospital of Lausanne (CHUV), UNIL, Switzerland	1.000000	0.05
Institute Gustave-Roussy (IGR), France	1.000000	0.05
Barbara Ann Karmanos Cancer Institute, Wayne State University, United States of America (USA)	1.000000	0.05
University of California, San Diego (UC San Diego), United States of America (USA)	1.000000	0.05
Yale Cancer Center, United States of America (USA)	1.000000	0.05
Ares Trading S.A., Switzerland	1.000000	0.05
Merck Sharp and Dohme de España S.A. (MSD Spain), Spain	1.000000	0.05
Irmandade da Santa Casa de Misericórdia de Porto Alegre, Brazil	1.000000	0.05
NIHR Biomedical Research Centre for Cancer, United Kingdom (UK)	1.000000	0.05
University General Hospital Attikon, Greece	1.000000	0.05
Aix-Marseille University (AMU), France	0.500000	0.03
IRCCS National Cancer Institute (INT) Milan, Italy	0.500000	0.03
University of Milan (UNIMI), Italy	0.500000	0.03
Brigham and Women's Hospital (BWH), United States of America (USA)	0.500000	0.03
Hospital Timone, France	0.500000	0.03

Interested in Oncology and Carcinogenesis?